Brown Advisory Inc. Has $630,000 Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Brown Advisory Inc. lessened its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 39.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 114,698 shares of the company’s stock after selling 75,557 shares during the period. Brown Advisory Inc. owned about 0.07% of Xeris Biopharma worth $630,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Bank of New York Mellon Corp boosted its position in shares of Xeris Biopharma by 11.8% during the 1st quarter. Bank of New York Mellon Corp now owns 360,324 shares of the company’s stock valued at $1,978,000 after purchasing an additional 37,949 shares in the last quarter. FNY Investment Advisers LLC purchased a new stake in shares of Xeris Biopharma in the first quarter worth approximately $63,000. Wealth Enhancement Advisory Services LLC raised its stake in shares of Xeris Biopharma by 92.1% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 31,254 shares of the company’s stock worth $172,000 after purchasing an additional 14,986 shares during the last quarter. Pallas Capital Advisors LLC purchased a new stake in shares of Xeris Biopharma in the first quarter worth approximately $84,000. Finally, Apella Capital LLC purchased a new stake in shares of Xeris Biopharma during the first quarter valued at approximately $55,000. Institutional investors own 42.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on XERS. Wall Street Zen downgraded Xeris Biopharma from a “buy” rating to a “hold” rating in a research report on Thursday, May 22nd. Oppenheimer raised their price target on Xeris Biopharma from $6.00 to $7.00 and gave the stock an “outperform” rating in a report on Friday, May 9th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $6.25.

Xeris Biopharma Stock Up 6.5%

Shares of XERS stock opened at $5.44 on Tuesday. The business has a 50-day moving average price of $4.74 and a two-hundred day moving average price of $4.31. Xeris Biopharma Holdings, Inc. has a 12-month low of $2.10 and a 12-month high of $6.07. The firm has a market cap of $850.71 million, a P/E ratio of -18.13 and a beta of 0.66.

Xeris Biopharma (NASDAQ:XERS) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. The firm had revenue of $57.80 million for the quarter, compared to the consensus estimate of $57.61 million. As a group, research analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Insider Buying and Selling at Xeris Biopharma

In related news, insider Kevin Mcculloch bought 25,000 shares of the stock in a transaction dated Friday, June 13th. The stock was bought at an average price of $4.38 per share, with a total value of $109,500.00. Following the purchase, the insider owned 1,708,585 shares in the company, valued at approximately $7,483,602.30. The trade was a 1.48% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 4.56% of the company’s stock.

Xeris Biopharma Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.